close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Marijuana-Schizophrenia Link in Brain Scans

December 8, 2005

Marijuana use may raise the risk of schizophrenia among adolescents already predisposed to the disease, a New York based researcher has suggested.

The finding is based on a series of small brain-imaging studies by Manzar Ashtari, PhD, of Zucker Hillside Hospital in Glen Oaks, NY. Dr Ashtari has identified a region of the brain that she says is still "under construction" during adolescence, and is affected by both schizophrenia and marijuana use.

Dr Ashtari presented the results of her studies at a Radiological Society of North America (RSNA) podium presentation on 1 December, and her findings were summarized on 1 December 2005 in a report by MedPage Today.

The results of studies in adolescents and schizophrenics strongly support the hypothesis that using marijuana is a risk factor for developing schizophrenia "if the teenager has a family history of schizophrenia," Dr Ashtari reportedly said at a press conference sponsored by the RSNA.

Brain-Imaging Study

Dr Ashtari and colleagues followed microscopic changes in the brain's arcuate fasciculus using diffusion-tensor imaging, a sophisticated brain-imaging method. The resulting tensor images "provide a more in depth study of the brain than magnetic resonance, which images only static water molecules," said Dr Ashtari, according to MedPage Today.

Four studies compared images from 12 healthy young adolescent boys' brains with images from 12 healthy older teenage boys' brains. Results showed several areas of the arcuate fasciculus "are still developing during early adolescence."

The arcuate fasciculus is a fibrous bundle that connects Broca's area (in the frontal lobe) and Wernicke's area (in the left temporal lobe). It is involved in speech development, language interpretation and several other higher-order functions, according to Dr Ashtari.

The researchers also compared brain-scans from 11 people with schizophrenia with those of 17 healthy, matched controls; they also compared brain-scans from 17 people with schizophrenia who used marijuana with 17 healthy, matched controls. The fourth study compared brain-scans from 15 people who used marijuana with scans from 15 matched non-marijuana users.

"We found that marijuana affects areas of the brain that are still developing during adolescence and these are the same areas that are affected by schizophrenia," Dr Ashtari said, according to MedPage Today.

Interpreting the Data

Dr Ashtari's findings should be cautiously interpreted, says Michael Brant-Zawadzki, MD, chairman of the RSNA's communication committee. "The numbers are small and the studies are from a single institution," he reportedly said.

An additional confounding factor concerns the mechanism of how marijuana may be affecting brain function. According to Dr Brant-Zawadzki, the arcuate fasciculus is an area of the brain in which "myelination continues throughout adolescence. So it is difficult to say if marijuana is disrupting this myelination process or it is merely delaying the process or if this is a chance finding."

Dr Ashtari agreed that the results of these studies must be confirmed in larger trials.

Sources:
RSNA: Brain Scans Suggest Marijuana-Schizophrenia Link, MedPage Today, 1 December 2005.
The Impact of Recurrent Exposure to Cannabis on Brain Development in Adolescents with Schizophrenia and Healthy Volunteers. Ashtari M et al, Radiological Society of North America.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...